What is RNAimmune?
Founded in 2020 and headquartered in Gaithersburg, Maryland, RNAimmune is at the forefront of discovering and developing messenger RNA (mRNA) therapeutics and vaccines. The company utilizes mRNA as a data carrier to enable the human body to produce therapeutic proteins, targeting a broad spectrum of diseases. As a spin-off from Sirnaomics, Inc., RNAimmune holds exclusive global rights to Sirnaomics' proprietary Polypeptide Lipid Nanoparticle (PLNP) technology for enhanced mRNA delivery. Furthermore, the company has developed an proprietary AI algorithm, ALEPVA, for advanced antigen prediction and vaccine design. By integrating these platform technologies, RNAimmune aims to build a comprehensive mRNA drug discovery and development pipeline to address significant unmet needs in viral infections, cancer, and rare diseases.
How much funding has RNAimmune raised?
RNAimmune has raised a total of $39.4M across 3 funding rounds:
Angel/Seed
$2.4M
Angel/Seed
$10M
Series A
$27M
Angel/Seed (2020): $2.4M with participation from Terra Magnum Capital Partners
Angel/Seed (2021): $10M led by Smooth River and Hongrun
Series A (2022): $27M supported by Smooth River and Sirnaomics
Key Investors in RNAimmune
Smooth River
Smooth River is an investor participating in the company's funding rounds, with a focus that is not explicitly detailed in the provided data.
Terra Magnum Capital Partners
Terra Magnum Capital Partners is an investment firm that has backed RNAimmune, likely focusing on companies within the biotechnology or pharmaceutical sectors.
Sirnaomics
Sirnaomics is a key investor and strategic partner, providing proprietary mRNA delivery technology and contributing to RNAimmune's development as a spin-off venture.
What's next for RNAimmune?
With its recent major strategic investment and a total funding base of $39.4M, RNAimmune is well-positioned for accelerated growth and pipeline expansion. The company's focus on proprietary delivery technology and AI-driven design suggests a strategic emphasis on efficiency and innovation in its therapeutic development. Future endeavors will likely involve advancing its preclinical and clinical programs, potentially forging new partnerships, and further solidifying its position in the competitive mRNA therapeutics market. The substantial backing indicates a strong belief in RNAimmune's potential to deliver impactful treatments.
See full RNAimmune company page
